Abstract
Purpose
This study investigates the combined effects of gemcitabine and trabectedin (ecteinascidin 743) in two pancreatic cancer cell lines and proposes a pharmacodynamic (PD) model to quantify their pharmacological interactions.
Methods
Effects of gemcitabine and trabectedin upon the pancreatic cancer cell lines MiaPaCa-2 and BxPC-3 were investigated using cell proliferation assays. Cells were exposed to a range of concentrations of the two drugs, alone and in combination. Viable cell numbers were obtained daily over 5 days. A model incorporating nonlinear cytotoxicity, transit compartments, and an interaction parameter ψ was used to quantify the effects of the individual drugs and combinations.
Results
Simultaneous fitting of temporal cell growth profiles for all drug concentrations provided reasonable cytotoxicity parameter estimates (the cell killing rate constant K max and the sensitivity constant KC 50) for each drug. The interaction parameter ψ was estimated as 0.806 for MiaPaCa-2 and 0.843 for BxPC-3 cells, suggesting that the two drugs exert modestly synergistic effects.
Conclusions
The proposed PD model enables quantification of the temporal profiles of drug combinations over a range of concentrations with drug-specific parameters. Based upon these in vitro studies, trabectedin may have augmented benefit in combination with gemcitabine. The PD model may have general relevance for the study of other cytotoxic drug combinations.
Similar content being viewed by others
References
Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29. doi:10.3322/caac.21208 (Epub 2014 Jan 7)
Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413
Peter GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP (2000) Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 87:227–253
Rinehart KL, Holt TG, Fregeau NL, Keifer PA, Wilson GR, Perun TJ Jr, Sakai R, Thompson AG, Stroh JG, Shield LS, Seigler DS, Li LH, Martin DG, Grimmelikhuijzen CJP, Gade G (1990) Bioactive compounds from aquatic and terrestrial sources. J Nat Prod 53:771–792
Cuevas C, Francesch A (2009) Development of Yondelis (trabectedin, ET-743): a semisynthetic process solves the supply problem. Nat Prod Rep 26:322–337
Mini E, Nobili S, Caciaqli B, Landini I, Mazzei T (2006) Cellular pharmacology of gemcitabine. Ann Oncol 17(Suppl 5):v7–12
D’Incalci M, Galmarini CM (2010) A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 9:2157–2163
Yip-Schneider MT, Sweeney CJ, Jung SH, Crowell PL, Marshall MS (2001) Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther 298:976–985
Cappella P, Tomasoni D, Faretta M, Lupi M, Montalenti F, Viale F, Banzato F, D’Incalci M, Ubezio P (2001) Cell cycle effects of gemcitabine. Int J Cancer 93:401–408
Tavecchio M, Natoli C, Ubezio P, Erba E, D’Incalci M (2007) Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unraveled by a novel mathematical simulation approach. Cell Prolif 40:885–904
Gajate C, An F, Mollinedo F (2002) Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis. J Biol Chem 277:41580–41589
Miller SC, Huang R, Sakamuru S, Shukla SJ, Attene-Ramos MS, Shinn P, Van Leer D, Leister W, Austin CP, Xia M (2010) Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem Pharmacol 79:1272–1280
Messersmith WA, Jimeno A, Ettinger D, Laheru D, Brahmer J, Lansey D, Khan Y, Donehower RC, Elsayed Y, Zannikos P, Hidalgo M (2008) Phase I trial of weekly trabectedin (Et-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol 63:181–188
Loewe S (1953) The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3:285–290
Gessner PK (1974) The isobolographic method applied to drug interactions. In: Moselli PL, Garattini S, Cohen SN (eds) Drug interactions. Raven Press, New York, pp 349–362
Terranova N, Germani M, Del Bene F, Magni P (2013) A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination. Cancer Chemother Pharmacol 72:471–482
Earp J, Krzyzanski W, Chakraborty A, Zamacona MK, Jusko WJ (2004) Assessment of drug interactions relevant to pharmacodynamics indirect response models. J Pharmacokinet Pharmacodyn 31:345–380
Goteti K, Garner CE, Utley L, Dai J, Ashwell S, Moustakas DT, Gönen M, Schwartz GK, Kern SE, Zabludoff S, Brassil PJ (2010) Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents. Cancer Chemother Pharmacol 66:245–254. doi:10.1007/s00280-009-1153-z
Lobo ED, Balthasar JP (2002) Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro. AAPS PharmSci 4:E42
Koch G, Walz A, Lahu G, Schropp J (2009) Modeling of tumor growth and anticancer effects of combination therapy. J Pharmacokinet Pharmacodyn 36:179–197
Chakraborty A, Jusko WJ (2002) Pharmacodynamic interaction of recombinant human interleukin-10 and prednisolone using in vitro whole blood lymphocyte proliferation. J Pharm Sci 91:1334–1342
Robertson TB (1923) The chemical basis of growth and senescence. J B Lippincott Company, Philadelphia
Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Presenti E, Germani M, Poggesi I, Rocchetti M (2004) Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 64:1094–1101
Rocchetti M, Simeoni M, Pesenti E, De Nicolao G, Poggesi I (2007) Predicting the active doses in humans from animal studies: a novel approach in oncology. Eur J Cancer 43:1862–1868
D’Argenio DZ, Schumitzky A, Wang X (2009) ADAPT 5 user’s guide: pharmacokinetic/pharmacodynamics systems analysis software. Biomedical Simulations Resource, Los Angeles
Ait-Oudhia S, Straubinger RM, Mager DE (2013) Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacy. J Pharmacol Exp Ther 344:103–112. doi:10.1124/jpet.112.199109 (Epub 2012 Oct 3)
Jusko WJ (1971) Pharmacodynamics of chemotherapeutic effects: dose-time–response relationships for phase-nonspecific agents. J Pharm Sci 60:892–895
Deer EL, González-Hernández J, Coursen JD, Shea JE, Ngatia J, Scaife CL, Firpo MA, Mulvihill SJ (2010) Phenotype and genotype of pancreatic cancer cell lines. Pancreas 39:425–435. doi:10.1097/MPA.0b013e3181c15963
Zhi JG, Nightingale CH, Quintilani R (1988) Microbial pharmacodynamics of pipercillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa. J Pharmacokinet Biopharm 16:355–375
Taamma A, Misset JL, Riofrio M, Guzman C, Brain E, Lopez Lazaro L, Rosing H, Jimeno JM, Cvitkovic E (2001) Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 19:1256–1265
Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE (2004) Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cell. Clin Cancer Res 10:2307–2318
Simeoni M, De Nicolao G, Magni P, Rocchetti M, Poggesi I (2013) Modeling of human tumor xenografts and dose rationale in oncology. Drug Discov Today Technol 10:e365–e372. doi:10.1016/j.ddtec.2012.07.004
Del Bene F, Germani M, De Nicolao G, Magni P, Re CE, Ballinari D, Rocchetti M (2009) A model-based approach to the in vitro evaluation of anticancer activity. Cancer Chemother Pharmacol 63:827–836
Woo S, Pawaskar D, Jusko WJ (2009) Methods of utilizing baseline values for indirect response models. J Pharmacokinet Pharmacodyn 36:381–408
Huang P, Plunkett W (1995) Induction of apoptosis by gemcitabine. Semin Oncol 22(4 Suppl 11):19–25
Bergman AM, Pinedo HM, Peters GJ (2002) Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updates 5:19–33
Arlt A, Gehrz A, Müerköster S, Vorndamm J, Kruse ML, Fölsch UR, Schäfer H (2003) Role of NF-kappaB and Akt/P13K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22:3243–3251
Chen D, Niu M, Jiao X, Zhang K, Liang J, Zhang D (2012) Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-kB signaling pathway in human pancreatic ductal adenocarcinoma. Int J Mol Sci 13:1186–1208. doi:10.3390/ijms13011186 (Epub 2012 Jan 20)
Kagawa S, Takano S, Yoshitomi H, Kimura F, Satoh M, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Furukawa K, Matsushita K, Nomura F, Miyazaki M (2012) Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. J Surg Res 178:758–767. doi:10.1016/j.jss.2012.05.065 (Epub 2012 Jun 12)
Karnitz LM, Flatten KS, Wagner JM, Loegering D, Hackbarth JS, Arlander SJ, Vroman BT, Thomas MB, Baek YU, Hopkins KM, Lieberman HB, Chen J, Cliby WA, Kaufmann SH (2005) Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 68:1636–1644
Battaglia MA, Parker RS (2011) Pharmacokinetic/pharmacodynamic modelling of intracellular gemcitabine triphosphate accumulation: translating in vitro to in vivo. IET Syst Biol 5:34. doi:10.1049/iet-syb.2009.0073
Acknowledgments
The authors would like to thank Prof. Wojciech Krzyzanski for valuable discussions. Trabectedin was a gift from PharmaMar. This work was supported by NIH Grants GM57980 and GM24211 to W.J.J. and CA168454 and CA198096 to R.M.S, the National Research Fund, Luxembourg, and co-funded under the Marie Curie Actions of the European Commission (FP7-COFUND).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
No conflicts of interest are reported.
Appendix
Appendix
The following provides a proof of Eqs. (5)–(10), assuming that drug concentrations are constant during experiments. The stationary equations of the proposed PD model Eqs. (3) and (4) are as below:
with
so that
To calculate the new steady state for single-agents, we solve Eqs. (11f) and (12) with respect to \(R_{\text{ss}}^{{\prime }}\) and obtain Eq. (6). In order to achieve that the number of cells decreases for t > 0, one needs \(R_{\text{ss}}^{'} \le R_{0}\), i.e., the threshold concentration is defined via
which is equivalent to
This leads to
as Eq. (5) is shown. To obtain total cell eradication, the concentration
is needed, i.e., C E,d is defined via
resulting in Eq. (7).
For combination effects, Eqs. (11f) and (12) provide
and Eq. (9) is obtained.
Rights and permissions
About this article
Cite this article
Miao, X., Koch, G., Straubinger, R.M. et al. Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells. Cancer Chemother Pharmacol 77, 181–193 (2016). https://doi.org/10.1007/s00280-015-2907-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-015-2907-4